Heron Therapeutics, Inc. /De/ (HRTX) Stock Price & Analysis
Heron Therapeutics, Inc. /De/ (HRTX) fell 10.74% to USD 0.4 as of June 10, 2026 at 03:35 UTC, according to Nexqual real-time market data.
HRTX last closed at USD 0.45; the session ranged USD 0.4–0.46 on volume of 4,358,980 shares. Market capitalization is $76.64M, with a 52-week range of USD 0.4–2.3 (NCM). Source: Nexqual, June 10, 2026 at 03:35 UTC.
Key Statistics (as of June 10, 2026 at 03:35 UTC)
| Price | USD 0.4 |
|---|---|
| Change | ▼ 10.74% (down) |
| Previous Close | USD 0.45 |
| Open | USD 0.46 |
| Day Range | USD 0.4 – 0.46 |
| 52-Week Range | USD 0.4 – 2.3 |
| Volume | 4,358,980 shares |
| Market Cap | $76.64M |
| Exchange | NCM |
Technical Analysis (HRTX)
Nexqual's technical model rates HRTX "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:35 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.95 (oversold) |
| vs SMA50 | Below (USD 0.91) |
| MACD | -0.15 (negative) |
Analyst Ratings (HRTX)
Wall Street analysts rate HRTX "Buy" based on 2 analysts, with a mean price target of USD 3 (range USD 2–4), per Nexqual as of June 10, 2026 at 03:35 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 3 |
| High Target | USD 4 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (HRTX)
| Next Earnings Date | 2026-08-07 |
|---|---|
| EPS Estimate | USD -0.02 |
| Revenue Estimate | $42.13M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.04 vs est -0.02 ▼ miss |
| 2025-12-31 | USD -0.02 vs est -0.03 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.01 ▼ miss |
| 2025-06-30 | USD -0.02 vs est -0.01 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financials & Fundamentals (HRTX)
| Total Revenue | $150.71M |
|---|---|
| Revenue Growth (YoY) | -10.80% |
| Gross Margin | +62.80% |
| Operating Margin | -13.73% |
| Profit Margin | -20.53% |
| Debt / Equity | 1,550.12 |
| Current Ratio | 2.53 |
| Total Cash | $44.78M |
| Total Debt | $141.63M |
| Free Cash Flow | $-18.44M |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Financial Health Score (HRTX)
Nexqual rates Heron Therapeutics, Inc. /De/'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:35 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 63%, operating -14% |
| Balance Sheet | Weak — $45M cash vs $142M debt |
| Cash Flow | Weak — FCF negative: -$18M, burning cash |
| Efficiency | Mixed — No data |
Ownership (HRTX)
| Insider Ownership | +0.88% |
|---|---|
| Institutional Ownership | +83.35% |
| Shares Outstanding | 189.28M |
| Float | 135.48M |
| Short % of Float | +27.05% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
Leadership (HRTX)
Heron Therapeutics, Inc. /De/ is led by Craig Alexander Collard (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 03:35 UTC.
| CEO & Director | Craig Alexander Collard (age 59) |
|---|---|
| Executive VP & CFO | Ira Duarte (age 56) |
| Executive VP & COO | Mark E. Hensley (age 42) |
| Vice President of Legal | Melissa Jarel |
| Vice President of Marketing | Ryan Craig |
Major Backers & Investors (HRTX)
Notable institutional backers of Heron Therapeutics, Inc. /De/ include Rubric Capital Management LP, Clearline Capital, LP, Orbimed Advisors LLC., according to Nexqual as of June 10, 2026 at 03:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 15.87% |
| Clearline Capital, LP | 6.46% |
| Orbimed Advisors LLC. | 5.19% |
| Velan Capital Investment Management LP | 4.62% |
| Millennium Management | 4.03% |
| Tejara Capital Ltd | 3.35% |
| Tang Capital Management, LLC | 3.3% |
| Palisade Capital Management, L.P. | 3.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.71% |
| BlackRock | 7.9% |
Source: Nexqual, June 10, 2026 at 03:35 UTC.
From Heron Therapeutics, Inc. /De/'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The FDA has various programs, including Breakthrough Therapy, Fast Track and Priority Review, which are intended to expedite or simplify the process for reviewing drug candidates, and/or provide for approval based on surrogate endpoints.
- Biochronomer Technology Our proprietary Biochronomer Technology is designed to deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a period from days to weeks with a single administration.
- We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to our Products and our Biochronomer Technology. 7   Some of the critical materials and components used in manufacturing our Products are sourced from single suppliers.
- Intellectual Property Our success will depend in large part on our ability to:   • obtain and maintain international and domestic patents and other legal protections for the proprietary technology, inventions and improvements we consider important to our business;   • prosecute and defend our patents;   • preserve our trade secrets; and   • operate without infringing the patents and proprietary rights of other parties.
Partnerships
- In January 2024, we entered into a co-promotion agreement with Crosslink Network to expand the sales network supporting ZYNRELEF.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| ESPR | Esperion Therapeutics, Inc. | USD 3.14 | ▲ 0.32% |
| ATRA | Atara Biotherapeutics, Inc. | USD 9.77 | ▼ 1.51% |
| KYNB | Kyntra Bio, Inc. | USD 6.69 | ▼ 0.3% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:35 UTC. This page is informational and not investment advice.